AGIO insider transaction filings
AGIOS PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-06. Screen AGIO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-06 | 4 | Gheuens Sarah — Chief Medical Officer | Sale (S): 30,000 @ $30.48 | EDGAR |
| 2026-07-10 | 4 | Backstrom Jay T. — Director | Grant/award (A): 1,447 @ $0 · Option exercise (M): 1,447 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 8,375 @ $0 · Sale (S): 4,007 @ $37.56 · Option exercise (M): 8,375 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Ballal Rahul D. — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Ho Maykin — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Owen Adams Catherine — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Scadden David — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Smith Cynthia — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Viswanadhan Krishnan — Chief Strategy and Operations | Option exercise (M): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Goff Brian — Chief Executive Officer, Director | Option exercise (M): 39,000 (derivative) @ $0 · Grant/award (A): 39,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Burns James William — Chief Legal Officer | Option exercise (M): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Jones Cecilia — Chief Financial Officer | Option exercise (M): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Milanova Tsveta — Chief Commercial Officer | Option exercise (M): 3,000 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Backstrom Jay T. — Director | Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | FOUSE JACQUALYN A — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Foster-Cheek Kaye I — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | CAPELLO JEFFREY D — Director | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Owen Adams Catherine — Director | Option exercise (M): 1,976 @ $0 · Option exercise (M): 1,976 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | CAPELLO JEFFREY D — Director | Option exercise (M): 1,976 @ $0 · Option exercise (M): 1,976 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Burns James William — Chief Legal Officer | Option exercise (M): 8,500 @ $0 · Sale (S): 3,280 @ $34.71 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 8,500 @ $0 · Sale (S): 2,940 @ $34.71 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Jones Cecilia — Chief Financial Officer | Option exercise (M): 8,500 @ $0 · Sale (S): 3,141 @ $34.71 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Milanova Tsveta — Chief Commercial Officer | Option exercise (M): 8,500 @ $0 · Sale (S): 3,262 @ $34.71 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Viswanadhan Krishnan — Chief Corp Dev & Strategy | Option exercise (M): 8,100 @ $0 · Sale (S): 2,959 @ $34.71 · Option exercise (M): 8,100 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Goff Brian — Chief Executive Officer, Director | Option exercise (M): 25,528 @ $0 · Sale (S): 12,472 @ $34.71 · Option exercise (M): 13,500 @ $0 · Sale (S): 6,596 @ $34.71 · Option exercise (M): 25,528 (derivative) @ $0 · Option exercise (M): 13,500 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Viswanadhan Krishnan — Chief Corp Dev & Strategy | Option exercise (M): 8,100 @ $0 · Sale (S): 2,959 @ $27.80 · Option exercise (M): 8,100 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Washburn Theodore James Jr. — Principal Accounting Officer | Sale (S): 5,272 @ $28.88 | EDGAR |
| 2026-03-03 | 4 | Goff Brian — Chief Executive Officer, Director | Option exercise (M): 8,500 @ $0 · Sale (S): 3,870 @ $28.96 · Option exercise (M): 18,000 @ $0 · Sale (S): 8,267 @ $28.96 · Option exercise (M): 13,000 @ $0 · Sale (S): 5,918 @ $28.96 · +5 more | EDGAR |
| 2026-03-03 | 4 | Burns James William — Chief Legal Officer | Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · Option exercise (M): 5,666 @ $0 · Sale (S): 1,681 @ $28.96 · Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · +8 more | EDGAR |
| 2026-03-03 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · Option exercise (M): 5,666 @ $0 · Sale (S): 1,681 @ $28.96 · Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · +6 more | EDGAR |
| 2026-03-03 | 4 | Jones Cecilia — Chief Financial Officer | Option exercise (M): 2,000 @ $0 · Sale (S): 594 @ $28.96 · Option exercise (M): 5,666 @ $0 · Sale (S): 1,681 @ $28.96 · Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · +8 more | EDGAR |
| 2026-03-03 | 4 | Milanova Tsveta — Chief Commercial Officer | Option exercise (M): 5,666 @ $0 · Sale (S): 1,681 @ $28.96 · Option exercise (M): 4,000 @ $0 · Sale (S): 1,187 @ $28.96 · Grant/award (A): 14,000 (derivative) @ $0 · Grant/award (A): 52,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-03-03 | 4 | Washburn Theodore James Jr. — Principal Accounting Officer | Option exercise (M): 2,350 @ $0 · Sale (S): 698 @ $28.96 · Option exercise (M): 2,450 @ $0 · Sale (S): 727 @ $28.96 · Option exercise (M): 2,695 @ $0 · Sale (S): 798 @ $28.96 · +4 more | EDGAR |
| 2026-03-03 | 4 | Viswanadhan Krishnan — Chief Corp Dev & Strategy | Grant/award (A): 14,000 (derivative) @ $0 · Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Milanova Tsveta — Chief Commercial Officer | Option exercise (M): 8,475 @ $0 · Sale (S): 2,872 @ $27.02 · Option exercise (M): 8,475 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Burns James William — Chief Legal Officer | Option exercise (M): 6,000 @ $0 · Sale (S): 2,932 @ $27.09 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Goff Brian — Chief Executive Officer, Director | Option exercise (M): 25,528 @ $0 · Sale (S): 12,473 @ $27.09 · Option exercise (M): 12,750 @ $0 · Sale (S): 6,230 @ $27.09 · Option exercise (M): 25,528 (derivative) @ $0 · Option exercise (M): 12,750 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 6,000 @ $0 · Sale (S): 2,932 @ $27.09 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Milanova Tsveta — Chief Commercial Officer | Option exercise (M): 6,000 @ $0 · Sale (S): 2,932 @ $27.09 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Jones Cecilia — Chief Financial Officer | Option exercise (M): 6,000 @ $0 · Sale (S): 2,932 @ $27.09 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Scadden David — Director | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $43.84 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 2,454 @ $25.01 · Sale (S): 2,454 @ $43.78 · Option exercise (M): 2,454 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 200 @ $25.01 · Sale (S): 200 @ $43.81 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-10-29 | 4 | Gheuens Sarah — Chief Medical Officer | Option exercise (M): 3,302 @ $25.01 · Sale (S): 3,302 @ $43.92 · Option exercise (M): 3,302 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | Scadden David — Director | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $41 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Scadden David — Director | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $40 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Jones Cecilia — Chief Financial Officer | Option exercise (M): 7,472 @ $0 · Sale (S): 3,651 @ $36.77 · Option exercise (M): 7,472 (derivative) @ $0 | EDGAR |
| 2025-09-09 | 4 | Washburn Theodore James Jr. — Principal Accounting Officer | Sale (S): 8,546 @ $36.87 | EDGAR |
| 2025-08-29 | 4 | Scadden David — Director | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $40 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
Recent 8-K events — AGIOS PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-04 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2025-07-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-06-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AGIO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →